Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.
about
Regenerative Therapy of Type 1 Diabetes Mellitus: From Pancreatic Islet Transplantation to Mesenchymal Stem CellsPancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence ReviewThe Influence of Immunosuppressive Agents on the Risk of De Novo Donor-Specific HLA Antibody Production in Solid Organ Transplant RecipientsTolerogenic Dendritic Cells on Transplantation: Immunotherapy Based on Second Signal BlockageUpdate on CD40 and CD154 blockade in transplant modelsBiologics in organ transplantationA programmable synthetic lineage-control network that differentiates human IPSCs into glucose-sensitive insulin-secreting beta-like cellsStereoselectivity of isoflurane in adhesion molecule leukocyte function-associated antigen-1Evolution of β-Cell Replacement Therapy in Diabetes Mellitus: Islet Cell TransplantationTransdisciplinary approach to restore pancreatic islet function.IL-2-Mediated In Vivo Expansion of Regulatory T Cells Combined with CD154-CD40 Co-Stimulation Blockade but Not CTLA-4 Ig Prolongs Allograft Survival in Naive and Sensitized MiceSafety and tolerability of the T-cell depletion protocol coupled with anakinra and etanercept for clinical islet cell transplantation.LFA-1-specific therapy prolongs allograft survival in rhesus macaques.LFA-1 blockade induces effector and regulatory T-cell enrichment in lymph nodes and synergizes with CTLA-4Ig to inhibit effector function.Islet Oxygen Consumption Rate (OCR) Dose Predicts Insulin Independence in Clinical Islet AutotransplantationHeterogeneity within T Cell Memory: Implications for Transplant ToleranceTolerogenic therapies in transplantation.Integrin antagonists prevent costimulatory blockade-resistant transplant rejection by CD8(+) memory T cells.Persufflation (or gaseous oxygen perfusion) as a method of organ preservationBelatacept and sirolimus prolong nonhuman primate islet allograft survival: adverse consequences of concomitant alefacept therapyTranscriptome analysis of GVHD reveals aurora kinase A as a targetable pathway for disease prevention.Transient combination therapy targeting the immune synapse abrogates T cell responses and prolongs allograft survival in mice.Islet transplantation in type 1 diabetes: ongoing challenges, refined procedures, and long-term outcomePrimate models in organ transplantationAnti-Leukocyte Function-Associated Antigen 1 Therapy in a Nonhuman Primate Renal Transplant Model of Costimulation Blockade-Resistant Rejection.Biologic agents in islet transplantation.Targeting co-stimulatory pathways: transplantation and autoimmunity.Tolerance--is it worth it?Islet cell xenotransplantation: a serious look toward the clinicOrofacial adverse effects of biological agents.Islet cell transplant: Update on current clinical trials.Memory T cells in organ transplantation: progress and challenges.Belatacept-Resistant Rejection Is Associated With CD28+ Memory CD8 T Cells.T Cell Cosignaling Molecules in Transplantation.Leukotoxin kills rodent WBC by targeting leukocyte function associated antigen 1.Selective Targeting of High-Affinity LFA-1 Does Not Augment Costimulation Blockade in a Nonhuman Primate Renal Transplantation Model.Advances in targeting co-inhibitory and co-stimulatory pathways in transplantation settings: the Yin to the Yang of cancer immunotherapy.Glial cell line-derived neurotrophic factor enhances human islet posttransplantation survival.Lineage conversion of mouse fibroblasts to pancreatic α-cells.Integrin antagonists for transplant immunosuppression: panacea or peril?
P2860
Q26752205-F9E2BC9F-BF56-4B1C-B2B1-3720BD3B031FQ26773701-F2BFCC88-DC14-4593-AE0A-082E553977E1Q26774993-A160EA3A-D574-4EF3-AD2F-E175A8F9BD70Q26778646-E94F4AC0-89E1-44AF-A094-CEF2201A77DFQ26798362-A49E2517-B6C3-4B5B-844D-85EFCB3DD1B0Q26829578-409B3ED2-3B5E-4DC4-B94F-378C026E086DQ27320218-47CFB6B3-1FDB-4366-B957-6C1E81B97969Q28538551-B9AFA385-D051-439B-8ACA-44AC9D536D5FQ30430239-4362D6AD-5343-4A47-9153-F2CBBB511896Q33357060-348D724B-F3F5-41B3-B2D8-849BCA609290Q33586165-DE222EB9-328E-4F13-9559-51890E0259EBQ33848529-D06F247F-3B10-4E39-809C-B113A7CEDBB1Q34364120-6E778B2D-962A-4D0F-AAEF-7898683A78A6Q35585966-9C026517-8978-4D6C-8185-8751ED0FBCABQ35741476-6BAADAEC-C00C-4D9D-BBA8-9E77B43FD6A1Q35927610-BEBAEEBE-6584-40DF-82A1-73D859E1851EQ36102133-4AD8943A-1523-4E16-8963-36EBADFF8DFFQ36305532-8EB5D555-3977-4A3D-A2A2-61CF50F07EB5Q36458671-BF960027-EF6D-4B62-9740-C92DFB278735Q36572728-F7272B2E-86DA-4E22-AB26-80866FAB22C8Q36925951-6E9FC33A-EA4F-4937-AC68-F8DB90360B6BQ37042924-B7491416-9A42-45DF-9CF6-AF7F63AC115BQ37088225-6538A700-1889-4CA2-9FC1-8D29241431AEQ37122367-C300D2AD-9218-4F7B-ABE2-7B0ADCEC2BF4Q37343737-20C68D08-BF91-49C7-93ED-C0AF7AD01846Q38126884-6F93857A-C80D-4129-ACF0-353E17E7A845Q38150101-8137D188-F689-4E99-BEFD-14D8780A0323Q38174023-F6B5EB27-9A9B-49CA-9A0C-69B1D9522E84Q38210098-14BE47D4-B293-4E4F-8A4D-86892488CB0DQ38213692-A76D3809-84A9-405A-8E26-F42A88CCBF41Q38689971-DEBF403E-9319-4AD9-B8A6-8BBCACF0F54CQ38753494-319D3ACE-E48B-4668-A21A-C6C552B0274BQ38787322-8689C672-92BF-473A-A708-13E5AFE5408DQ38837473-2AD1551C-E9D9-489D-AB41-8D127FD259D2Q39065493-760F5816-884F-4EEC-BFD9-BF92F354A4DFQ39152748-6B8D34A0-C9C0-49F6-BE41-EFB93040C868Q39161011-500E12C3-3061-4197-8DF6-96180A936005Q39484224-1A5B5A5D-A07D-47FD-8B72-82537DFC0D28Q41071196-2DB4B547-E0CD-4E27-999B-4CCF25F102E3Q42108235-68A4E1AA-41EE-4FC8-8878-C537DB1D00EA
P2860
Experience with a novel efalizumab-based immunosuppressive regimen to facilitate single donor islet cell transplantation.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Experience with a novel efaliz ...... or islet cell transplantation.
@ast
Experience with a novel efaliz ...... or islet cell transplantation.
@en
type
label
Experience with a novel efaliz ...... or islet cell transplantation.
@ast
Experience with a novel efaliz ...... or islet cell transplantation.
@en
prefLabel
Experience with a novel efaliz ...... or islet cell transplantation.
@ast
Experience with a novel efaliz ...... or islet cell transplantation.
@en
P2093
P2860
P1476
Experience with a novel efaliz ...... nor islet cell transplantation
@en
P2093
C P Larsen
I R Badell
J J Hutchinson
N A Turgeon
P2860
P304
P356
10.1111/J.1600-6143.2010.03212.X
P407
P577
2010-09-01T00:00:00Z